Breaking News

Financial Report: AMRI 


May 6, 2014

Decline in royalties impacts results

AMRI 

 
1Q Revenues: $59.3 million (flat)

1Q Earnings: $3.5 million (-46%)

Comments: Contract revenue was $51.0 million in the quarter, up 10%. Royalties were $8.3 million, down 36% due to generic competition for Allegra in Japan. Discovery Services and Development / Small Scale Manufacturing (DDS) contract revenue for the first quarter was $19.5 million, a decrease of 3%. Decreases in Discovery revenues were partially offset by increases in Development/Small Scale Manufacturing. Large Scale Manufacturing contract revenue was $31.5 million, up 19%.

blog comments powered by Disqus
  • 16th Annual $alary $urvey

    16th Annual $alary $urvey

    Tim Wright, Editor||June 3, 2015
    Welcome to Contract Pharma’s Sixteenth Annual Salary Survey! This year’s results are derived from more than 500 respondents f

  • Newsmakers: PCI

    Newsmakers: PCI

    Tim Wright, Editor||June 2, 2015
    PCI execs talk about the recent opening of the company’s new North American clinical facility, as well as other trends in the market

  • How Sterilization of Primary Packaging Influences the Results of E&L Studies

    How Sterilization of Primary Packaging Influences the Results of E&L Studies

    Thorsten Sogding, Daniel Canton, Daniel Haines, Uwe Rothhaar, SCHOTT Pharma Services ||June 2, 2015
    As the demands that are being placed on the quality and stability of medications continue to increase, the interactions that take place between the primary packaging container and filled drug product are becoming increasingly important